Table 1.
Baseline characteristics of patients by pacing modality.
| BiV (n = 13) | HBP (n = 27) | LBBP (n = 10) | p Value | |
|---|---|---|---|---|
| Characteristics | ||||
| Age [years] | 70 (67–73.5) | 71 (62–75) | 69 (67–78) | 0.888 |
| Male sex | 7 (53.8%) | 10 (37.0%) | 7 (70.0%) | 0.196 |
| QRS [ms] | 98 (±7) | 100 (±13) | 105 (±15) | 0.145 |
| Heart rate [bpm] | 128 (113–137) | 133 (123–141) | 127 (97–132) | 0.278 |
| Atrial flutter | 2 (15.4%) | 6 (22.2%) | 3 (30.0%) | 0.815 |
| LVEF [%] | 38 (35–40) | 39 (30–45) | 28 (20–42) | 0.135 |
| LAVI [mL/m2] | 55 (±11) | 55 (±11) | 59 (±14) | 0.975 |
| Initial median NYHA class | 3 | 3 | 3 | 0.175 |
| Comorbidities | ||||
| AH | 9 (69.2%) | 17 (63.0%) | 8 (80.0%) | 0.665 |
| Diabetes | 3 (23.1%) | 8 (29.6%) | 2 (20.0%) | 0.914 |
| CAD | 6 (46.2%) | 6 (22.2%) | 4 (40.0%) | 0.260 |
| Medication | ||||
| ACEi/ARB/ARNI | 9 (69.2%) | 20 (74.1%) | 6 (60.0%) | 0.716 |
| MRA | 7 (53.8%) | 9 (33.3%) | 5 (50.0%) | 0.434 |
| BB | 13 (100%) | 25 (92.6%) | 9 (90.0%) | 0.767 |
| Digoxin | 5 (38.5%) | 7 (25.9%) | 2 (20.0%) | 0.640 |
| Amiodarone | 2 (15.4%) | 6 (22.2%) | 1 (10.0%) | 0.887 |
| Anticoagulation | 13 (100%) | 25 (92.6%) | 10 (100%) | 1 |
| Loop diuretic | 7 (53.8%) | 17 (63.0%) | 7 (70.0%) | 0.794 |
BIV: biventricular pacing; HBP: His bundle pacing; LBBP: left bundle branch pacing; LVEF: left ventricle ejection fraction; LAVI: left atrial volume index; AH: arterial hypertension; CAD: coronary artery disease; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; ARNI: angiotensin receptor neprilysin inhibitor; MRA: mineralocorticoid receptor antagonist; BB: beta blocker.